Skip to main content

UCB Medicines: Clinical Studies and Scientific Research Publication

Publications

  1. Our Science
FILTER
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

Select product(s):
Select topic(s):
Phase:
phase 2

ZILBRYSQ® (zilucoplan)

Generalized Myasthenia
Gravis
View

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial

James F Howard Jr, Nowak J Richard, Wolfe I Gil et al.  May 01, 2020
phase 2

BIMZELX® (bimekizumab-bkzx)

Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
View

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study 

Desiree van der Heijde, Gensler S. Lianne, Deodhar Atul et al.  April 06, 2020
phase 2

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

Christopher T Ritchlin, Kavanaugh Arthur, Joseph F Merola et al.  February 08, 2020
phase 3

CIMZIA® (certolizumab pegol)

Non-radiographic Axial Spondyloarthritis
View

A 52-week randomized placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. 

Deodhar A, Gensler L, Kay J et al.  May 28, 2019
phase 3

CIMZIA® (certolizumab pegol)

Rheumatoid Arthritis
View

Efficacy and safety of certolizumab pegol plus methotrexate in patients with rheumatoid arthritis: 3-year data from the RAPID 2 study. 

Smolen JS, van Vollenhoven RF, Kavanaugh A et al.  April 30, 2019
phase 3

CIMZIA® (certolizumab pegol)

Plaque Psoriasis
View

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study. 

Lebwohl M, Blauvelt A, Paul C et al.  April 14, 2018
phase 3

CIMZIA® (certolizumab pegol)

Plaque Psoriasis
View

Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from two phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). 

Gottlieb A, Blauvelt A, Diamant T et al.  April 13, 2018
phase 2

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.

Krueger James, Feldman Steven, Umezawa Yoshinori et al.  March 30, 2018
phase 2

Plaque Psoriasis
View

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial

K.A. Papp, J. F. Merola, A. B. Gottlieb et al.  March 30, 2018
phase 3

CIMZIA® (certolizumab pegol)

Psoriatic Arthritis
View

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. 

van der Heijde D, Deodhar A, FitzGerald O et al.  March 14, 2018